Friday, 25 September 2026European Markets

EASE2PAY NV Stock Was 29.43% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with EASE2PAY NV (EAS2P.AS) jumping 29.43% to €0.69 on Friday while AEX-Index fell 0.92% to €925.23.

EASE2PAY NV's last close was €0.53, 48.04% below its 52-week high of €1.02.

About EASE2PAY NV

Ease2pay N.V. provides online payment services and platforms in the Netherlands. The company operates payment transaction platform, which offers users services to order and pay in one action; and parking solutions. It also operates a platform that connects travelers with providers of parking and charging facilities on the road and water. The company was formerly known as DOCDATA N.V. and changed its name to Ease2pay N.V. in February 2018. Ease2pay N.V. is based in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, EASE2PAY NV has a trailing twelve months EPS of €-0.06.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -18.14%.

Moving Average

EASE2PAY NV's worth is way higher than its 50-day moving average of €0.57 and way higher than its 200-day moving average of €0.59.

Yearly Top and Bottom Value

EASE2PAY NV's stock is valued at €0.69 at 22:32 EST, way under its 52-week high of €1.02 and way higher than its 52-week low of €0.52.

More news about EASE2PAY NV (EAS2P.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com